OTC labeling reform to be discussed at FDA public hearing on Sept. 29.
This article was originally published in The Rose Sheet
Executive Summary
OTC DRUG LABELING CONSUMER COMPREHENSION ISSUES TO BE DISCUSSED at a public hearing scheduled for Sept. 29 at FDA headquarters. The hearing is intended to solicit information and opinions on "various aspects of OTC drug labeling design that would improve the communication of information to consumers" and will examine whether consumers currently understand the information presented in OTC labels.